Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.66 |
| ▸ | GLP1R | P43220 | 6/20 | 0.58 |
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | GIPR | P48546 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373287 | 0.97 | TFPI (0.66) | TFPIGLP1RBACE1BACE2VIPR1 | |
| SCHEMBL30721576 | 0.94 | TFPI (0.61) | TFPI | |
| SCHEMBL30861920 | 0.94 | TFPI (0.65) | TFPIGLP1RBACE1BACE2VIPR1 | |
| SCHEMBL29373682 | 0.94 | TFPI (0.68) | TFPIGLP1RBACE1BACE2VIPR1 | |
| SCHEMBL29375967 | 0.93 | TFPI (0.59) | TFPI | |
| SCHEMBL30721553 | 0.93 | TFPI (0.66) | TFPIGLP1RBACE1BACE2VIPR1 | |
| SCHEMBL30429902 | 0.92 | TFPI (0.68) | TFPIGLP1RBACE1BACE2VIPR1 | |
| SCHEMBL31000935 | 0.92 | TFPI (0.65) | TFPIGLP1RVIPR1 | |
| SCHEMBL30836920 | 0.92 | TFPI (0.66) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL29525489 | 0.91 | TFPI (0.63) | TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505533-B1 | SYNTHESIS METHOD FOR LOW-RACEMIZATION IMPURITY LIRAGLUTIDE | SHENZHEN JYMED TECH CO LTD (CN) | 2025-01-15 | — | — | EP | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| EP-3505533-B1 | SYNTHESIS METHOD FOR LOW-RACEMIZATION IMPURITY LIRAGLUTIDE | SHENZHEN JYMED TECH CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | TFPI 525/4885GLP1R 1/4885BACE1 569/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | TFPI 525/4885GLP1R 1/4885BACE1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.